Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-05-31
2008-12-16
Ketter, James S (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C607S050000, C435S173800
Reexamination Certificate
active
07465546
ABSTRACT:
Methods and devices are described for the regulation of Transforming Growth actor (TGF)-β1, β2, and/or β3 protein gene expression in bone cells and other tissues via the capacitive coupling or inductive coupling of specific and selective electric fields to the bone cells or other tissues, where the specific and selective electric fields are generated by application of specific and selective electric and electromagnetic signals to electrodes or one or more coils or other field generating device disposed with respect to the bone cells or other tissues so as to facilitate the treatment of diseased or injured bone and other tissues. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone and other tissue that include generating specific and selective electric and electromagnetic signals that generate fields in the target tissue optimized for increase of TGF-β1, β2, and/or β3 protein gene expression and exposing bone and other tissue to the fields generated by specific and selective signals so as to regulate TGF-β1, β2, and/or β3 protein gene expression in such tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, in the treatment of osteoporosis, and in other conditions in which TGF-β1, β2, and/or β3 protein may be implicated.
REFERENCES:
patent: 4430999 (1984-02-01), Brighton et al.
patent: 4442846 (1984-04-01), Brighton et al.
patent: 4467808 (1984-08-01), Brighton et al.
patent: 4467809 (1984-08-01), Brighton
patent: 4487834 (1984-12-01), Brighton
patent: 4506674 (1985-03-01), Brighton et al.
patent: 4509520 (1985-04-01), Dugot
patent: 4535775 (1985-08-01), Brighton et al.
patent: 4549547 (1985-10-01), Brighton et al.
patent: 4600010 (1986-07-01), Dugot
patent: 4683873 (1987-08-01), Cadossi et al.
patent: 4998532 (1991-03-01), Griffith
patent: 5014699 (1991-05-01), Pollack et al.
patent: 5038797 (1991-08-01), Batters
patent: 5269746 (1993-12-01), Jacobson
patent: 5273033 (1993-12-01), Hoffman
patent: 5338286 (1994-08-01), Abbott et al.
patent: 5374283 (1994-12-01), Flick
patent: 5743844 (1998-04-01), Tepper et al.
patent: 5968527 (1999-10-01), Litovitz
patent: 6083149 (2000-07-01), Wascher et al.
patent: 6132362 (2000-10-01), Tepper et al.
patent: 6186940 (2001-02-01), Kirschbaum
patent: 6261221 (2001-07-01), Tepper et al.
patent: 6485963 (2002-11-01), Wolf et al.
patent: 6605089 (2003-08-01), Michelson
patent: 6747004 (2004-06-01), Tabibzadeh
patent: 6919205 (2005-07-01), Brighton
patent: 6955642 (2005-10-01), Simon
patent: 7022506 (2006-04-01), Brighton et al.
patent: 7130692 (2006-10-01), Brighton et al.
patent: 7158835 (2007-01-01), Brighton et al.
patent: 7167753 (2007-01-01), Brighton et al.
patent: 7215995 (2007-05-01), Brighton et al.
patent: 2002/0052634 (2002-05-01), March
patent: 2002/0125769 (2002-09-01), Riley et al.
patent: 2003/0211084 (2003-11-01), Brighton et al.
patent: 2004/0138709 (2004-07-01), Brighton
patent: 2005/0203591 (2005-09-01), Brighton
patent: 2006/0190043 (2006-08-01), Brighton et al.
patent: 2006/0235473 (2006-10-01), Brighton
patent: 2007/0299472 (2007-12-01), Brighton
patent: 1198580 (2006-05-01), None
patent: 00/02585 (2000-01-01), None
patent: 01/62336 (2001-08-01), None
patent: 2005/070136 (2005-08-01), None
Aaron, R.K., et al., “Stimulation of experimental endochondral ossification by low-energy pulsing electromagnetic fields,”J. Bone Miner. Res., Nov. 2, 1989, 4, 227-233.
Aaron, R.K., et al., “The conservative treatment of osteonecrosis of the femoral head,”Clin. Orthop., 1989, 249, 209-218.
Bassett, C.A.L., et al., “Effects of pulsed electromagnetic fields on Steinberg ratings of femoral head osteonecrosis,”Clin. Orthop., Sep. 1989, 246, 172-185.
Bassett, C.A.L., et al., “Fundamental and practical aspects of therapeutic uses of pulsed electromagnetic fields (PEMSs),”Crit. Rev. Biomed. Eng., 1989, 17(5), 451-529.
Bassett, C.A.L., et al., “Pulsing electromagnetic field treatment in ununited fractures and failed arthrodeses,”JAMA, Feb. 5, 1982, 247(5), 623-628.
Bassett,C.A.L., “Low energy pulsing electromagnetic fields modify biomedical processes,”BioEssays, 1987, 6(1) , 36-42.
Binder, A., et al., “Pulsed electromagnetic field therapy of persistent rotator cuff tendonitis,”Lancet, Mar. 31, 1984, 695-698.
Brighton, C.T., et al., “A multicenter study of the treamtent of non-union with constant direct current,”J. Bone and Joint Surgery, Jan. 1981, 62-A(1), 2-13.
Brighton, C.T., et al., “Fracture healing in the rabbit fibula when subjected to various capacitively coupled electrical fields,”J. Orthop. Res., 1985, 3, 331-340.
Brighton, C.T., et al., “In vitro bone-cell response to a capacitively coupled electrical field,”Clin. Orthop. Related Res., Dec. 1992, 285, 255-262.
Brighton, C.T., et al., “Increased cAMP production after short-term capacitively coupled stimulation in bovine growth plate chondrocytes,”J. Orthop. Res., 1988, 6, 552-558.
Brighton, C.T., et al., “Signal transduction in electrically stimulated bone cells,”J. Bone Joint Surg. Am., 2001, 83-A(10), 1514-1523.
Brighton, C.T., et al., “Treatment of castration-induced osteoporosis by a capacitively coupled electrical signal in rat vertebrae,”J. Bone and Joint Surgery, Feb. 1989, 71-A(2), 228-236.
Brighton, C.T., et al., “Treatment of denervation/disuse osteoporosis in the rat with a capacitively coupled electrical signal: effects on bone formation and bone resorption,”J. Orthop. Res., 1988, 6, 676-684.
Brighton, C.T., et al., “Treatment of recalcitrant non-union with a capacitively coupled electrical field,”J. Bone and Joint Surgery, Apr. 1985, 67-A(4), 577-585.
Carter, E.L., et al., “Field distributions in vertebral bodies of the rat during electrical stimulation: a parametric study,”IEEE Trans. on Biomed. Eng., Mar. 1989, 36(3), 333-345.
Goodman, R., et al., “Exposure of salivery gland cells to low-frequency electromagnetic fields alters polypeptide synthesis,”Proc. Natl. Acad. Sci. USA, Jun. 1988, 85, 3928-3932.
Goodwin, C.B., et al., “A double-blind study of capacitively coupled electrical stimulation as an adjunct to lumbar spinal fusions,”Spine, 1999, 24(13), 1349-1356.
Grodzinsky, A.J., “Electromechanical and physicochemical properties of connective tissue,”Crit. Rev. Biomed. Engng., 1983, 9(2), 133-198.
Harrison, M.H.M., et al., “Use of pulsed electromagnetic fields in perthes disease: report of a pilot study,”J. Pediatr. Orthop., 1984, 4, 579-584.
Jones, D.B., et al., “PEMF effects on differentiation and division in mirine melanoma cells are mediated indirectly through cAMP,”Trans. BRAGS6, 1986, 51.
Lorich, D.G., et al., “Biochemical pathway mediating the response of bone cells to capacitive coupling,”Clin. Orthop. and Related Res., 1998, 350, 246-256.
Massardo, L., et al., “Osteoarthritis of the knee joint: an eight year prospective study,”Ann Rheum Dis., 1989, 48, 893-897.
Mooney, V., “A randomized double-blind prospective study of the efficacy of pulsed electromagnetic fields for inter body lumbar fusions,”Spine, 1990, 15(7), 708-712.
Norton, L.A., et al., “Pulsed electromagnetic fields alter phenotypic expression in chondroblasts in tissue culture,”J. Orthop. Res., 1988, 6, 685-689.
Pienkowski, D., et al., “Low-power electromagnetic stimulation of osteotomized rabbit fib
Ketter James S
The Trustees Of The University of Pennsylvania
Woodcock & Washburn LLP
LandOfFree
Regulation of transforming growth factor-beta (TGF-β)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of transforming growth factor-beta (TGF-β)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of transforming growth factor-beta (TGF-β)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035654